127 related articles for article (PubMed ID: 35533805)
1. An overview of CDK3 in cancer: clinical significance and pharmacological implications.
Teo T; Kasirzadeh S; Albrecht H; Sykes MJ; Yang Y; Wang S
Pharmacol Res; 2022 Jun; 180():106249. PubMed ID: 35533805
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.
Braun K; Hölzl G; Soucek T; Geisen C; Möröy T; Hengstschläger M
Oncogene; 1998 Oct; 17(17):2259-69. PubMed ID: 9811456
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of cdk2 and cdk3 on the control of pRb and E2F function during G1 exit.
Hofmann F; Livingston DM
Genes Dev; 1996 Apr; 10(7):851-61. PubMed ID: 8846921
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
Khleif SN; DeGregori J; Yee CL; Otterson GA; Kaye FJ; Nevins JR; Howley PM
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4350-4. PubMed ID: 8633069
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
8. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
10. Deregulated expression of CDK2- or CDK3-associated kinase activities enhances c-Myc-induced apoptosis.
Braun K; Hölzl G; Pusch O; Hengstschläger M
DNA Cell Biol; 1998 Sep; 17(9):789-98. PubMed ID: 9778038
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation.
Zheng D; Cho YY; Lau AT; Zhang J; Ma WY; Bode AM; Dong Z
Cancer Res; 2008 Sep; 68(18):7650-60. PubMed ID: 18794154
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins.
Zariwala M; Liu J; Xiong Y
Oncogene; 1998 Nov; 17(21):2787-98. PubMed ID: 9840943
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
Keenan SM; Lents NH; Baldassare JJ
J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
[TBL] [Abstract][Full Text] [Related]
14. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
15. Cdk3-promoted epithelial-mesenchymal transition through activating AP-1 is involved in colorectal cancer metastasis.
Lu J; Zhang ZL; Huang D; Tang N; Li Y; Peng Z; Lu C; Dong Z; Tang F
Oncotarget; 2016 Feb; 7(6):7012-28. PubMed ID: 26755651
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
17. A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition.
Kaulich M; Link VM; Lapek JD; Lee YJ; Glass CK; Gonzalez DJ; Dowdy SF
Sci Rep; 2021 Jul; 11(1):14736. PubMed ID: 34282211
[TBL] [Abstract][Full Text] [Related]
18. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.
Clark W; Black EJ; MacLaren A; Kruse U; LaThangue N; Vogt PK; Gillespie DA
Mol Cell Biol; 2000 Apr; 20(7):2529-42. PubMed ID: 10713176
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
20. Cyclin C/cdk3 promotes Rb-dependent G0 exit.
Ren S; Rollins BJ
Cell; 2004 Apr; 117(2):239-51. PubMed ID: 15084261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
